GSK acquires Alzheimer's vaccine and ends oncology deal
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinehas acquired the exclusive rights to develop and commercialise Affiris's Alzheimer's disease vaccine programmes for €22.5 million upfront.